Connect with us

Technology

Implicity’s EVIDENCE-RM Study Demonstrates Marked Improvement in ICD Patient Outcomes

Published

on

Comprehensive analysis of real-world data shows significant clinical and medico-economic advantages of Implicity’s universal, alert-based remote monitoring platform

CAMBRIDGE, Mass., April 24, 2025 /PRNewswire/ — IMPLICITY®, a leader in remote patient monitoring and cardiac data management solutions, today unveiled new findings from its EVIDENCE-RM study¹. Leveraging extensive data from the French National Health Data System (SNDS), the study demonstrated clear clinical and medico-economic benefits associated with Implicity’s universal monitoring system (UMS) compared to conventional, manufacturer-specific systems, including Abbott, Biotronik, Boston Scientific, and Medtronic.

The study, recently published in Heart Rhythm, analyzed clinical outcomes and costs for over 69,000 patients with implantable cardioverter-defibrillators (ICDs) and defibrillators with cardiac resynchronization therapy (CRT-Ds). Patients remotely monitored using Implicity’s platform showed increased survival rates and a reduction in both the number and duration of all-cause and heart failure-related hospitalizations, resulting in substantial healthcare cost reductions. Key findings attributed to Implicity’s IM009² platform include:

26% reduction in mortality (HR, 0.74; 95% CI, 0.73–0.77; P=.001)4% decrease in HF hospitalizations, total corrected healthcare costs, and mean duration of hospitalization17.8% decrease in hospital-related costs, primarily driven by decreased costs in cardiovascular disease careIncremental Cost-Effectiveness Ratio (ICER) of approximately –$112 USD (-103€) per Day Alive and Out of Hospital (DAOH) based on the French Healthcare System

“Managing patients with ICDs and CRTs presents considerable challenges, since they are at high risk of hospitalization due to arrhythmias and heart failure,” said Dr. Niraj Varma, Professor of Medicine and Director, Cardiac Pacing & Tachyarrhythmia Devices at the Cleveland Clinic. “The EVIDENCE-RM study clearly demonstrates that a universal monitoring solution operating alert-based remote monitoring can significantly reduce these risks, improving patient outcomes and substantially lowering healthcare costs. This is an important advancement in our ability to proactively manage patients with ICDs and CRTs.”

“These findings mark a pivotal moment in remote cardiac care and prove Implicity’s effectiveness with unparalleled clinical results,” stated Implicity CEO Dr. Arnaud Rosier. “A 26% reduction in mortality and better use of healthcare resources highlight the impact of universal remote monitoring, driven by AI, over fragmented manufacturer-specific systems. Implicity is committed to driving innovation so that every cardiac patient receives proactive, efficient care.”

For more information about Implicity and the EVIDENCE-RM study, please visit www.implicity.com.

About Implicity
Implicity is a digital MedTech software company dedicated to providing the best remote care to patients with cardiac implantable electronic devices and heart failure. Co-founded by cardiac electrophysiologist Arnaud Rosier, MD, PhD, the platform aggregates, normalizes, and standardizes data from any implantable cardiac device across all manufacturers, improving care for patients with cardiac implants and heart failure.

Implicity’s platform provides critical health information augmented by FDA-cleared AI³ algorithms, enabling healthcare providers to make more informed decisions for better patient outcomes. With access to the Health Data Hub, one of the world’s largest databases of heart disease patients, Implicity is able to develop its AI solutions based on more robust data. The company is protecting more than 100,000 patients in over 200 medical facilities across the US and Europe. To learn more, visit www.implicity.com

Health Data Hub is a health data platform established by the French government to combine existing health patient databases and facilitate their usage for research and development purposes

References

N. Varma et al., “Impact of a universal monitoring system (‘third party’) on outcomes of ICD patients: A nationwide study,” Heart Rhythm, 2024.IM009: 2021. Manufacturer: Implicity. IM009 is a software as a medical device (SaMD) intended to be used as an adjunct of a remote monitoring platform to follow-up target population patients. IM009 is compatible with devices with remote monitoring feature such as cardiac implantable electronic devices and connected weight scales. The three main intents of IM009 are to (1) label observations generated by medical devices according to predefined categories, (2) create clinically relevant observations for worsening atrial fibrillation and/or rapid weight gain in the context of heart failure, based on data recorded by the device and (3) label Atrial Fibrillation burden observations generated by cardiac implantable electronic device (CIED) as to be hidden or relevant for health care provider based on patient’s anticoagulation status. Hence, IM009 is designed to reduce the workload burden of healthcare providers/professionals in charge of reviewing the observations received from the patients’ devices. IM009 is not intended for use in life supporting or sustaining systems or Alarm devices and as a solely means of diagnosis. It is offered to healthcare providers/professionals on an advisory basis only in conjunction with the physician’s knowledge of ECG patterns, patient background, clinical history, symptoms, and other diagnostic information. Class I, according to Medical Device Directive 93/42/EEC. See the instructions for use for more information. Covered under the conditions defined in Article L. 162-52 of the French Social Security Code.IM007: 2021. ILR ECG ANALYZER created by Implicity is intended to be used by qualified healthcare professionals for the assessment of arrhythmias in Insertable Cardiac Monitor (ICM) ECG data. ILR ECG ANALYZER supports downloading and analyzing data recorded in compatible formats from ICMs. This version of the ILR ECG ANALYZER only supports ECG data from Medtronic ICMs. ILR ECG ANALYZER is intended to be electronically interfaced with other computer systems (remote monitoring platforms) that supply the ECG data to ILR ECG ANALYZER and receive the output of ILR ECG ANALYZER (analysis) for viewing by healthcare professionals. ILR ECG ANALYZER provides ECG signal processing and analysis, to detect asystole, bradycardia, atrial tachycardia or atrial fibrillation, ventricular tachycardia, normal rhythm and artifacts. ILR ECG ANALYZER is not for use in life supporting or sustaining systems or ECG monitor and Alarm devices. ILR ECG ANALYZER interpretation results are not intended to be the sole means of diagnosis. It is offered to physicians and clinicians on an advisory basis only in conjunction with the physician’s knowledge of ECG patterns, patient background, clinical history, symptoms, and other diagnostic information. ILR ECG ANALYZER is interfaced with the compatible remote monitoring platform from which it receives compatible ICM data file input (Medtronic LNQ11 Medtronic REVEAL XT 9529 Medtronic REVEAL DX 9528) and to which it transmits the output. Read carefully all instructions before use. Results: sensitivity: 98.64 % (509/516), false positive rate: 24.03 % (68/283). FDA cleared Class II medical device and CE marked Class I medical device (under medical device directive 93/42).
SignalHF FDA cleared Class II medical device and CE marked Class IIa (under MDR) medical device. Manufacturer: Implicity. The SignalHF System is intended for use by qualified healthcare professionals (HCP) managing patients over 18 years old who are receiving physiological monitoring for Heart Failure surveillance and implanted with a compatible Cardiac Implantable Electronic Devices (CIED) (i.e., compatible pacemakers, ICDs, and CRTs). The SignalHF System provides additive information to use in conjunction with standard clinical evaluation. The SignalHF HF Score is intended to calculate the risk of HF for a patient in the next 30 days. This System is intended for adjunctive use with other physiological vital signs and patient symptoms and information and is not intended to independently direct therapy.
See the instructions for use for more information.

Media Contact:
Sam Choinski
eMedia Junction
860-301-5058
samantha@emediajunction.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/implicitys-evidence-rm-study-demonstrates-marked-improvement-in-icd-patient-outcomes-302436176.html

SOURCE Implicity

Continue Reading

Technology

Seatrium and Karpowership Sign Contract for a Series of Whale Class Powership Conversion and Integration Projects

Published

on

By

SINGAPORE, Oct. 23, 2026 /PRNewswire/ — Seatrium Limited and its strategic partner, floating power leader Karpowership, have strengthened their longstanding collaboration with the award of a contract for the development, major conversion and integration of Karpowership’s third-generation hydrogen-ready Whale Class Powerships, reinforcing both companies’ commitment to delivering reliable, flexible and sustainable energy solutions to meet growing global electricity demand.

Under the contract, Seatrium will undertake the major conversion work and integration of five Whale Class Powerships. Seatrium’s scope of work encompasses equipment integration, mechanical completion and pre-commissioning works. Engineering activities are currently underway – both parties are working closely to advance the project’s execution phase progressively, with the first vessel in the series targeted for arrival in Seatrium Tuas Boulevard Yard in December 2027.

Powerships are floating power plants equipped with hydrogen-ready multi-fuel generation systems and integrated onboard substations that connect directly to national electricity grids. Leveraging Karpowership’s plug-and-play design, they can begin generating electricity in as little as 30 days. The next-generation Whale Class offers Karpowership’s highest capacity, engineered to deploy up to 600 MW of immediate, grid-ready power using an ultra-efficient footprint optimised for seamless, continuous fuel supply.

By combining advanced power generation technologies with maritime engineering excellence, these vessels will enhance energy security while providing the flexibility to support diverse market requirements.

Mr Alvin Gan, Executive Vice President, Repairs and Upgrades, Seatrium, said, “This significant milestone marks Seatrium’s first major conversion work and integration of Karpowership’s Whale Class Powerships. We are proud to support Karpowership’s drive to pioneer innovative floating power solutions and the next phase of its fleet development, bringing our capabilities in complex vessel integration and offshore engineering to the project. We thank Karpowership for the continued trust and look forward to advancing cutting-edge floating solutions that bolster energy resilience worldwide.”

Building on a strategic relationship established in 2018, Seatrium and Karpowership share an ambition to deepen their partnership and shape the next generation of energy infrastructure, strengthening energy resilience in Singapore and worldwide.

Mr Gokhan Kocak, Chief Technical Operations Officer, Karpowership, said, “Karpowership has transformed global power generation with its innovative Powership model, delivering fast-track and dependable electricity solutions to millions worldwide. The next-generation Whale Class Powerships demonstrate our continued commitment to innovation, operational excellence and energy security. We are pleased to build on our strong partnership with Seatrium, whose proven expertise in complex vessel integration make them an ideal partner.”

The contract marks the next step following an earlier Letter of Intent (LOI) signed in August 2025, solidifying the long-term partnership between the two companies. The LOI had provided for three FSRU conversions and the potential integration of up to six new-generation Powerships. Since 2018, Seatrium has successfully delivered seven FSRU conversion projects to Karpowership, with the eighth and ninth FSRU conversion projects secured this year.

View original content to download multimedia:https://www.prnewswire.com/news-releases/seatrium-and-karpowership-sign-contract-for-a-series-of-whale-class-powership-conversion-and-integration-projects-302917514.html

SOURCE Karpowership

Continue Reading

Technology

Scage Future Announces Effective Date for ADS Ratio Change

Published

on

By

NANJING, China, Oct. 22, 2026 /PRNewswire/ — Scage Future (“Scage Future” or the “Company”) (Nasdaq: SCAG), a provider of new energy and zero-emission heavy-duty commercial vehicles and e-fuel solutions, today announced the effective date and new CUSIP number for the previously announced change in the ratio of its American Depositary Shares (“ADSs”) to its ordinary shares (the “ADS Ratio”), from the current ADS Ratio of one (1) ADS to one (1) ordinary share to a new ADS Ratio of one (1) ADS to fifteen (15) ordinary shares (the “ADS Ratio Change”). The ADS Ratio Change will be effective on October 27, 2026 (the “Effective Date”).

For Scage Future’s ADS holders, the change in the ADS Ratio will have the same effect as a one-for-fifteen reverse ADS split. On the Effective Date, holders of ADSs will be entitled to receive one (1) new ADS for every fifteen (15) existing ADSs then held, and the exchange will occur automatically, with the then-held ADSs being cancelled and new ADSs being issued by Citibank, N.A., as the depositary bank for the Company’s ADS program (the “Depositary Bank”). Holders of ADSs will not be required to take any action in connection with the ADS Ratio Change.

No fractional new ADSs will be issued in connection with the change in the ADS Ratio. Instead, fractional entitlements to new ADSs will be aggregated and sold by the Depositary Bank, and the net cash proceeds from the sale of the fractional ADS entitlements (after deduction of fees, taxes and expenses) will be distributed to the applicable ADS holders by the Depositary Bank.

The change in the ADS Ratio will have no impact on Scage Future’s underlying ordinary shares, and no ordinary shares will be issued or cancelled in connection with the change in the ADS Ratio. Scage Future’s ADSs will continue to be traded on the Nasdaq Global Market under the symbol “SCAG.” In connection with the ADS Ratio Change, the CUSIP number for the ADSs will change from 80590A105 to a new CUSIP number of 80590A204, effective as of the Effective Date.

As a result of the change in the ADS Ratio, the ADS trading price is expected to increase proportionally, although the Company can give no assurance that the ADS trading price after the change in the ADS Ratio will be equal to or greater than fifteen times the ADS trading price before the change.

About Scage Future

Scage Future is a leading zero-emission technology provider in China, dedicated to decarbonizing global commercial transportation through its portfolio of advanced heavy-duty NEV trucks and innovative e-fuel systems. Through strategic partnerships with top-tier vehicle manufacturers and a strong quality control framework, the Company delivers intelligent, high-performance NEVs addressing the transport needs across logistics, mining and port operations. The Company has a proven track record in the design, production, and testing of next-generation heavy-duty NEVs, including the Dragon II plug-in hybrid dump truck, Galaxy II plug-in hybrid truck, and autonomous tractor trailer.

Forward-Looking Statements

Certain statements in this announcement are forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding the completion of the ADS Ratio Change on the Effective Date, the anticipated effects of the ADS Ratio Change on the trading price of the Company’s ADSs, and the Company’s expectations regarding the treatment of fractional ADS entitlements and the exchange of existing ADSs for new ADSs. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as “approximates,” “assesses,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may” or similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequently occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and other filings with the U.S. Securities and Exchange Commission.

For more information, please contact:

Scage Future
Investor Relations
Emily Wang
Head of Investor Relations
Email: scageIR@scagefd.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/scage-future-announces-effective-date-for-ads-ratio-change-302917128.html

SOURCE Scage Future

Continue Reading

Technology

Hanwha Power Receives ABS Approval in Principle for 1,700 TEU Battery-Powered Containership Design

Published

on

By

Fully electric propulsion design featuring approximately 151 MWh of energy storage strengthens capabilities in zero-carbon maritime transportIntegrated solution combines electric propulsion, and containerized battery energy storage systemsExpanded eco-friendly marine propulsion portfolio lays the groundwork for entry into the next-generation zero-carbon vessel market

SEOUL, South Korea, Oct. 23, 2026 /PRNewswire/ — Hanwha Power announced that it had received Approval in Principle (AiP) from the American Bureau of Shipping (ABS) for its design of a 1,700 TEU battery-powered containership.

The certificate presentation ceremony took place on October 22, local time, at the MHE (Maritime Hybrid, Electric & Hydrogen Fuel Cells) Conference & Exhibition 2026 in Bergen, Norway. Jong-kyu Hwang, Vice President, Technology Solutions at Hanwha Power, attended the ceremony alongside senior representatives from ABS. The event runs from October 21 to 23 at the Scandic Hotel Bergen City.

The newly approved design concept features a fully electric container vessel powered by a large-scale 151 MWh Energy Storage System (ESS). Electrical energy stored in containerized battery units serves as the vessel’s primary propulsion source, enabling operation without direct carbon emissions through the use of port charging infrastructure.

The use of containerized batteries, which can be handled and stowed like standard cargo containers, enhances space efficiency, maximizes cargo capacity, and optimizes overall vessel performance. This approach also supports flexible battery replacement and scalable operation, offering a practical pathway for the decarbonization of short-sea and regional container transport.

The AiP strengthens Hanwha Power’s capabilities in fully electric vessel design using large-scale battery energy storage and expands its portfolio of marine propulsion solutions. The company plans to build on this achievement to pursue opportunities in the next-generation zero-carbon maritime transport market.

Alongside the approval, Hanwha Power has also completed the basic design of a 1,000 TEU battery-powered container vessel. Building on its expertise in vessel design across multiple ship classes, the company aims to develop a comprehensive lineup of electric-propulsion vessels tailored to a wide range of operating conditions and customer needs.

“This AiP from ABS marks an important step in extending Hanwha Power’s marine technology capabilities to fully electric vessels powered by large-scale battery systems,” said Jong-kyu Hwang, Vice President, Technology Solutions at Hanwha Power. “We will address the needs of the next-generation zero-carbon maritime transport market with integrated solutions that combine electric propulsion and containerized battery system technologies.”

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/hanwha-power-receives-abs-approval-in-principle-for-1-700-teu-battery-powered-containership-design-302917556.html

Continue Reading

Trending